- Home
- PHK vs CRON Comparison
PHK vs CRON Comparison
Compare PHK & CRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHK
- CRON
- Stock Information
- Founded
- PHK 2003
- CRON N/A
- Country
- PHK United States
- CRON Canada
- Employees
- PHK N/A
- CRON N/A
- Industry
- PHK Finance/Investors Services
- CRON Medicinal Chemicals and Botanical Products
- Sector
- PHK Finance
- CRON Health Care
- Exchange
- PHK Nasdaq
- CRON Nasdaq
- Market Cap
- PHK 842.0M
- CRON 961.2M
- IPO Year
- PHK N/A
- CRON N/A
- Fundamental
- Price
- PHK $4.86
- CRON $2.52
- Analyst Decision
- PHK
- CRON
- Analyst Count
- PHK 0
- CRON 0
- Target Price
- PHK N/A
- CRON N/A
- AVG Volume (30 Days)
- PHK 491.5K
- CRON 1.3M
- Earning Date
- PHK 01-01-0001
- CRON 11-06-2025
- Dividend Yield
- PHK 12.61%
- CRON N/A
- EPS Growth
- PHK N/A
- CRON N/A
- EPS
- PHK N/A
- CRON 0.08
- Revenue
- PHK N/A
- CRON $132,357,000.00
- Revenue This Year
- PHK N/A
- CRON $19.67
- Revenue Next Year
- PHK N/A
- CRON $30.56
- P/E Ratio
- PHK N/A
- CRON $32.78
- Revenue Growth
- PHK N/A
- CRON 19.00
- 52 Week Low
- PHK $4.13
- CRON $1.60
- 52 Week High
- PHK $5.15
- CRON $3.16
- Technical
- Relative Strength Index (RSI)
- PHK 48.96
- CRON 52.38
- Support Level
- PHK $4.85
- CRON $2.43
- Resistance Level
- PHK $4.91
- CRON $2.58
- Average True Range (ATR)
- PHK 0.04
- CRON 0.08
- MACD
- PHK 0.01
- CRON 0.01
- Stochastic Oscillator
- PHK 66.67
- CRON 64.86
About PHK Pimco High Income Fund
PIMCO High Income Fund is a closed-end management investment company. The company's primary investment objective is to seek high current income. Its secondary objective is to seek capital appreciation.
About CRON Cronos Group Inc.
Cronos Group Inc headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the U.S., the company has an option to acquire 5.9% of U.S. multistate operator PharmaCann on a fully diluted basis upon easing of federal prohibition.